Application value of bevacizumab combined with pemetrexed and pluscisplatin first-line chemotherapy in treating lung cance r
10.3969/J.ISSN.1672-8270.2014.07.037
- VernacularTitle:贝伐单抗联合培美曲塞加顺铂一线化疗方案在肺癌中的应用价值研究
- Author:
Huiqin GENG
- Publication Type:Journal Article
- Keywords:
Lung cancer;
Chemotherapy;
Bevacizumab;
Vascular endothelial growth factor
- From:
China Medical Equipment
2014;(7):99-101,102
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To study the application value of bevacizumab combined with pemetrexed + pluscisplatin first-line chemotherapy in treating lung cancer. Methods: Advanced non small cell lung cancer patients from January 2011 to December 2012 were enrolled and randomly divided into observation group given bevacizumab combined with pemetrexed + pluscisplatin and control group given pemetrexed +pluscisplatin. Then long-term therapeutic effect index, tumor endocrine index and long-term therapeutic effect index were observed. Results:(1)overall remission condition of observation group were better than those of control group(u=6.782, P<0.05), objective response rate(x2=8.382, P<0.05) and disease control rate(x2=5.992, P<0.05) of observation group were higher than those of control group,the difference was statistically significant(P<0.05);(2)after chemotherapy, VEGF-A, VEGF-B and VEGF-C levels of two groups were lower than those before chemotherapy and VEGF-A(t=6.263, P<0.05), VEGF-B(t=6.094, P<0.05) and VEGF-C(t=5.892, P<0.05) levels of observation group were lower than those of control group, the difference was statistically significant(P<0.05);(3)1 year(x2=6.883, P<0.05), 3 year(x2=7.273, P<0.05) and 5 year(x2=6.274, P<0.05) survival rate and progression free survival(t=9.752, P<0.05), overall survival time(t=7.883, P<0.05) of observation group were higher than those of control group, the difference was statistically significant(P<0.05). Conclusion: Bevacizumab combined with pemetrexed+pluscisplatin have positive clinical value for it is helpful to improve the remission, decreased the level of vascular endothelial growth factor, inhibit tumor angiogenesis, prolonged overall survival time.
